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To the editor:
We recently published a report validating point-of-care 
rapid diagnostic tests (RDT) for the diagnosis of Hepatitis 
B virus (HBV) infection [1]. We believe that expedited and 
cost-effective diagnosis of HBV infection via RDT is criti-
cal to understand the epidemiology of HBV in resource-
limited settings and implement prevention and treatment 
strategies [2]. In that report, a whole-blood rapid test for 
HBV surface antigen (HBsAg), the universally accepted 
test to diagnose chronic HBV infection, in the form of 
“cassette” did not produce reliable results, with a sensitiv-
ity of only 56% (albeit a specificity of 100%). In the cur-
rent report, we validated a whole-blood RDT for HBsAg in 
the form of a test-strip (PRECHECK Bio Inc, Korea). The 
test was validated in 55 HBV positive (HBV-pos) and 20 
HBV negative (HBV-neg) individuals in the Netherlands. 
The median age was 38 years (IQR 3–47) in the HBV-pos 
group, with 60% being male and 33 years (IQR 30–37) 
in the HBV-neg group, with 85% being male. The RDT 
showed 100% sensitivity and specificity, with complete 
correlation for HBsAg positive and negative results with 
the local gold standard at Erasmus University, Rotterdam 
(LIAISON XL, Diaorin, Italy). All HBV-pos individuals were 
negative for hepatitis C and D virus, as well as human 
immunodeficiency virus. The samples included individu-
als on treatment and inactive carriers, all HBV genotypes 
other than F, with the most common genotypes being D 
(23%), C (20%), and A (15%). Median HBV DNA was 20 
IU/ml (IQR 20–285), median HBsAg level 510 IU/ml (IQR 
150–2900), and 16 subjects (29%) were HBeAg positive. 
Seventy percent of HBV+ individuals were on treatment 
(47% on entecavir and 21% on tenofovir). 
We believe this addition to our previous study is impor-
tant as it provides validation of a RDT for HBsAg using 
whole blood, in a rapid and cost-effective manner, there-
fore allowing the test to be used without the need of 
any laboratory resources. Our test was validated in one 
institution (Erasmus MC, the Netherlands) in a variety 
of genotypes. However, we believe further validation in 
resource-constrained settings will be of importance. 
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LETTERS TO THE EDITOR
Validation of Whole Blood Rapid Diagnosis Test for 
Hepatitis B
Jose D. Debes*,†, Gertine van Oord† and Andre Boonstra†
We recently published a report validating point-of-care rapid diagnostic tests (RDT) for the diagnosis 
of Hepatitis B virus (HBV) infection in serum. In the current report, we validated a whole-blood RDT for 
HBsAg in the form of a test-strip. The test was validated in 55 HBV positive individuals across all geno-
types other than F, and in 20 HBV negative individuals in the Netherlands. The RDT showed 100% sensi-
tivity and specificity. The low cost and use in whole blood allows this RDT to be useful in resource-limited 
locations, further validation in such settings will be of importance.
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